Lori A. Leslie, MD

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Looking to the future, Lori A. Leslie, MD, offers closing thoughts on unmet needs and potential improvements in the lymphoma treatment space.

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.

Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, discusses the benefits of implementing CAR T-cell therapy programs for patients with hematologic malignancies and highlights the successes with administering CAR T-cell therapy that JTCC has experienced.

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Closing out her discussion on novel therapy for relapsed/refractory follicular lymphoma, Lori Leslie, MD, highlights unmet needs and considers future evolutions in the treatment paradigm.

Insight to the factors that help select optimal third-line treatment for patients with follicular lymphoma in the context of available novel therapies.

A comprehensive overview of the third-line treatment armamentarium for patients with relapsed/refractory follicular lymphoma.

Key opinion leader Lori Leslie, MD, sheds light on the optimal sequencing of therapy throughout multiple lines of follicular lymphoma.

An expert’s perspective on assessing response to therapy in follicular lymphoma and the parameters used to identify high-risk disease.

Expert hematologist-oncologist Lori Leslie, MD, provides insight to the incidence and prognosis of follicular lymphoma, highlighting a patient case of refractory disease.

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.